The effects of intracerebroventricular (i.c.v.) administration of corticotropin-releasing factor (CRF) on plasma glucose and insulin levels were investigated in lean Zucker (FA/?) rats; i.c.v. CRF induced a rapid (within 1 min), marked, but transient increase in insulinemia that was not accompanied by any change in glycemia. At a time when insulinemia already returned toward basal values, glycemia started to increase. The effect of i.c.v. CRF in stimulating plasma insulin levels was dose-dependent and could be blocked by pretreatment of the animals with atropine methylnitrate. Similar results were obtained when studying the acute effects of i.c.v. CRF in genetically obese (fa/fa) rats. Although, in absolute values, the amount of insulin released in response to i.c.v. CRF was higher in obese than in lean animals, it was similar in both groups of rats, when expressed as fold increase over basal insulin levels. In summary, i.c.v. CRF elicits a rapid, vagally mediated stimulatory effect on insulin secretion both in lean and genetically obese fa/fa rats with no qualitative or quantitative difference between the two groups of animals. The site(s) of action of this CRF effect on insulinemia remains to be elucidated.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.